Table 3. Clinical Activity in Nivolumab-Treated Patients.^☆.

Variable	All Patients (N = 23)	Failure of Both Stem-Cell Transplantation and Brentuximab (N = 15)	No Stem-Cell Transplantation and Failure of Brentuximab (N = 3)	No Brentuximab Treatment (N = 5)†
Best overall response — no. (%)
Complete response	4 (17)	1 (7)	0	3 (60)
Partial response	16 (70)	12 (80)	3 (100)	1 (20)
Stable disease	3 (13)	2 (13)	0	1 (20)
Progressive disease	0	0	0	0
Objective response
No. of patients	20	13	3	4
Percent of patients (95% CI)	87 (66–97)	87 (60–98)	100 (29–100)	80 (28–99)
Progression-free survival at 24 wk — % (95% CI)‡	86 (62–95)	85 (52–96)	NC§	80 (20–97)
Overall survival — wk
Median	NR	NR	NR	NR
Range at data cutoff¶	21–75	21–75	32–55	30–50

^☆NC denotes not calculated, and NR not reached.

^†In this group, two patients had undergone autologous stem-cell transplantation and three had not.

^‡Point estimates were derived from Kaplan–Meier analyses; 95% confidence intervals were derived from Greenwood's formula.

^§The estimate was not calculated when the percentage of data censoring was above 25%.

^¶Responses were ongoing in 11 patients.